Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - teriflunomid - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva b.v., holandsko - teriflunomid - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

msn labs europe limited, malta - teriflunomid - 59 - immunopraeparata

Európska únia - slovenčina - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - roztrúsená skleróza - selektívne imunosupresíva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Európska únia - slovenčina - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Európska únia - slovenčina - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reddy holding gmbh, nemecko - fingolimod - 59 - immunopraeparata

Európska únia - slovenčina - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - roztrúsená skleróza - Ďalšie lieky na nervový systém - fampyra je indikovaná na zlepšenie chôdze u dospelých pacientov s roztrúsenou sklerózou s postihnutím v chôdzi (expanded disability status scale 4-7).

Európska únia - slovenčina - EMA (European Medicines Agency)

biogen netherlands b.v. - dimetylfumarát - roztrúsená skleróza - imunosupresíva - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Európska únia - slovenčina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresíva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.